Effectiveness of 17-α-hydroxyprogesterone caproate on preterm birth prevention in women with history-indicated cerclage

Am J Perinatol. 2013 Oct;30(9):755-8. doi: 10.1055/s-0032-1332799. Epub 2013 Jan 22.

Abstract

Objective: To determine whether 17-α-hydroxyprogesterone caproate (17P) reduces the incidence of preterm birth in women with a history-indicated cerclage.

Study design: Retrospective cohort study of women who received a cerclage for a prior preterm birth, analyzed based on exposure to 17P. The primary outcome variable was delivery < 35 weeks. Secondary outcomes were preterm birth < 37, 32, 28, and 24 weeks; interval between cerclage placement and delivery; gestational age at delivery; and infant birth weight.

Results: Fourteen women received 17P and 80 did not. Baseline characteristics did not differ between these two groups. Preterm delivery at < 35 weeks did not differ between those who received 17P and those who did not (29% versus 15%, p = 0.46). There were no significant differences between the groups for any other outcome.

Conclusion: 17P does not appear to have an effect on preterm birth < 35 weeks in women with a history-indicated cerclage.

MeSH terms

  • 17 alpha-Hydroxyprogesterone Caproate
  • Adult
  • Birth Weight
  • Cerclage, Cervical
  • Cervical Length Measurement
  • Female
  • Gestational Age
  • Humans
  • Hydroxyprogesterones / therapeutic use*
  • Pregnancy
  • Premature Birth / prevention & control*
  • Progestins / therapeutic use*
  • Retrospective Studies
  • Time Factors
  • Uterine Cervical Incompetence / drug therapy

Substances

  • Hydroxyprogesterones
  • Progestins
  • 17 alpha-Hydroxyprogesterone Caproate